Gram-positive Bacterial Infections Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Prevalence of Gram-Positive Infections

In 2024, invasive S. aureus bloodstream infections reached 37.9 per 100,000 population in EU/EEA countries, ranking second only to E. coli bacteremia. The backlog of surgeries during the pandemic has led to an increase in prosthetic joint implantations, raising the risk of late-onset staphylococcal infections over the lifespan of these devices. Between 2020 and 2024, the incidence of invasive S. pneumoniae disease doubled as respiratory pathogens began circulating more widely. Clostridioides difficile remains the leading cause of healthcare-associated diarrhea, resulting in 223,900 hospitalizations and 12,800 deaths annually in the U.S. Additionally, recurrence rates after vancomycin therapy remain as high as 30%.

Increasing Number of Drug Approvals & Late-Stage Pipelines

The 2025 antibacterial pipeline includes 90 clinical-stage assets, with half targeting gram-positive organisms. Tostatoxumab, a human monoclonal antibody, successfully completed Phase 3 trials for severe S. aureus pneumonia, demonstrating significant benefits for elderly patients and prompting a confirmatory study focused on this demographic. The anti-biofilm antibody TRL1068 showed promising results in Phase 1 trials for prosthetic joint infections, achieving synovial penetration and bacterial load reduction, thereby validating non-traditional treatment approaches. 

Growing Healthcare Spending in Emerging Economies

Between 2020 and 2025, China’s healthcare spending grew at an annual rate of 8.2%, driving demand for culture-based susceptibility testing and premium antimicrobials. During the same period, India increased its public health expenditure from 1.3% to 2.1% of GDP, improving access to diagnostics in non-metropolitan areas. GCC countries allocated USD 4.2 billion to laboratory upgrades between 2023 and 2025 to meet accreditation requirements mandating species-level identification within 48 hours. 

Adoption Of Rapid Molecular Diagnostics Enabling Targeted Therapy

The growing adoption of rapid molecular diagnostics is improving the management of gram-positive bacterial infections by enabling earlier and more accurate identification of pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, and vancomycin-resistant enterococci (VRE). Advanced diagnostic technologies, including multiplex PCR assays, MALDI-TOF mass spectrometry, and syndromic testing panels, are reducing the time required for pathogen identification and antimicrobial susceptibility assessment compared with conventional culture-based methods. Faster diagnosis allows clinicians to initiate targeted therapies sooner, optimize antibiotic selection, and reduce the inappropriate use of broad-spectrum antibiotics. As healthcare systems increasingly emphasize antimicrobial stewardship and improved clinical outcomes, the adoption of rapid molecular diagnostics is expected to support growth in the gram-positive bacterial infections market.

Escalating Antibiotic Resistance Among Gram-Positive Pathogens

The growing prevalence of difficult-to-treat gram-positive bacterial infections has increased dependence on newer and more expensive antimicrobial therapies, creating financial challenges for healthcare providers and payers. For instance, recently approved antibiotics designed for severe bacterial infections often carry a substantially higher treatment cost than conventional generic antibiotics, which can limit their adoption, particularly in cost-conscious healthcare settings. In addition, antimicrobial stewardship programs frequently reserve these novel therapies for patients with limited treatment options, reducing their routine use and slowing market uptake. These factors may restrict the widespread adoption of advanced treatment options and act as a restraint on the growth of the gram-positive bacterial infections market.

Patent Expiries Driving Generic Erosion

The expiration of patents for established therapies used in the treatment of gram-positive bacterial infections is intensifying generic competition and placing downward pressure on branded drug revenues. As lower-cost generic alternatives enter the market, healthcare providers and payers increasingly favor cost-effective treatment options, reducing the commercial potential of innovator products. For instance, the launch of generic versions of widely used antibiotics has accelerated price erosion across mature therapeutic segments, limiting revenue growth opportunities for branded manufacturers. This pricing pressure, combined with the high costs and risks associated with antibiotic development, may discourage investment in novel anti-infective therapies and act as a restraint on the growth of the gram-positive bacterial infections market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Gram-positive Bacterial Infections Market Segment Analysis

Diagnostics represented the smaller revenue base in 2026, yet they are set to post a 6.79% CAGR through 2032, the swiftest growth among product categories. Stewardship mandates that favor same-day organism detection reinforce hospital demand for multiplex PCR panels and rapid phenotypic systems. Glycopeptides retained an 18% slice of therapeutic revenue, but margin pressure is accelerating as clinical guidance adopts shorter, higher-dose courses requiring therapeutic drug monitoring. 

Rapid testing also underpins greater use of oral step-down regimens, boosting oxazolidinone demand. Hospitals gain workflow efficiencies when multiplex systems reduce ancillary culture labor, while payers view faster de-escalation as a lever to trim length of stay. These operational savings are beginning to offset the higher upfront cost of molecular tests, further widening the diagnostics adoption curve and enlarging the gram-positive bacterial infections market. 

Staphylococcus aureus infections, including methicillin-resistant strains, delivered 28.5% of 2026 pathogen revenue, reflecting their central role in surgical site and indwelling device infection. Despite a 20.4% decline in MRSA bloodstream incidence across the EU, hospital networks still reserve anti-MRSA cephalosporins and lipoglycopeptides for high-risk cohorts. 

Clostridioides difficile is projected to grow at 6.96% CAGR to 2032, the fastest pathogen trajectory, fueled by agents such as CRS3123 and ibezapolstat that spare gut microbiota and sharply cut recurrence. Regulatory agencies are signaling acceptance of composite endpoints that emphasize sustained cure, a development likely to accelerate approval timelines and solidify commercial uptake once Phase 3 data read out. 

Sepsis and bloodstream infections will advance at a 7.15% CAGR through 2032. Laboratories adopting rapid phenotypic AST slash turnaround from 72 hours to around seven, letting clinicians narrow therapy within the first day of positivity. Earlier streamlining supports reduced nephrotoxic exposure and smaller pharmacy budgets, encouraging wider deployment. 

Pneumonia maintained 24.95% of revenue in 2026, with MRSA and macrolide-resistant S. pneumoniae shaping empirical guideline updates that include high-dose amoxicillin or respiratory fluoroquinolones. Enhanced vaccine serotype coverage ahead of 2027 is expected to rebalance prescribing toward narrow beta-lactams, moderating pneumonia revenue growth relative to sepsis. 

Hospitals generated 45.40% of end-user spending in 2026; critical care wards and transplant centers remain heavy consumers of intravenous anti-staphylococcal agents and rapid assays. Even so, reference laboratories are forecast to expand at a 7.89% CAGR because they amortize the capital cost of NGS workflows across large sample volumes. 

The joint Cepheid–Oxford Nanopore project will further lower barriers by linking sample preparation on GeneXpert with real-time sequencing, yielding organism ID and resistance prediction in one shift. Such integrated pipelines are well-suited to reference lab environments where volume aggregation keeps per-test pricing competitive, helping those facilities gain share of the gram-positive bacterial infections market. 

Geography Analysis

North America Gram-positive Bacterial Infections Market

North America delivered 41.25% of 2026 revenue, anchored by 6,200 U.S. hospital laboratories and sustained capital budgets for rapid molecular systems. Urban facilities favor platforms such as Accelerate Pheno and BioFire FilmArray; however, rural centers still rely on manual culture workflows that can exceed 96 hours before result release, leaving opportunity for low-footprint direct-from-blood solutions. Federal stewardship targets now link reimbursement bonuses to timely de-escalation metrics, further entrenching rapid diagnostics. 

Europe Gram-positive Bacterial Infections Market

Europe recorded a 20.4% decline in MRSA bloodstream incidence from 2019 to 2024, yet eight countries documented vancomycin-resistant Enterococcus faecium prevalence above 50%. Germany’s 2025 technology assessment endorsed reimbursement for systems that trim AST turnaround by at least 12 hours. QuickMIC validation met this threshold, prompting procurement consortia to negotiate volume-linked contracts. With combined penicillin and macrolide resistance in S. pneumoniae at 11.1%, guideline panels now recommend empiric regimens containing either higher-dose beta-lactams or fluoroquinolones in community-acquired pneumonia. 

APAC and South America Gram-positive Bacterial Infections Market

Asia-Pacific is poised for an 8.25% CAGR through 2032, the highest regional pace. China’s 8.2% annual healthcare spending expansion between 2020 and 2025 has lifted procurement budgets for automated blood culture and MALDI-TOF identification. India’s Ayushman Bharat scale-up enables district hospitals to transition from syndromic management to culture-based therapy. Harmonization with EUCAST breakpoints across China, India, and Brazil tightens susceptibility interpretation for glycopeptides and oxazolidinones, reducing treatment failure masquerading as susceptibility. South America contributes 6% of global 2025 revenue; Brazil’s breakpoint adoption is already steering hospitals toward reserve agents for refractory VRE and MRSA infections.